Wockhardt to Launch New Drug Every 2-3 Years, Focus on Novel Antibiotics

• Wockhardt chairman Dr. Habil Khorakiwala announced plans to launch a new drug every two to three years for the next 10-15 years, with 5-6 new drugs scheduled in the next 4-5 years.
• The company's strategy focuses on novel antibiotics to combat drug resistance, an area largely abandoned by large pharmaceutical companies.
• Wockhardt's pipeline includes Zaynich (Zidebactam/Cefepime) seeking USFDA approval, WCK 6777 (Odrate) with USFDA Fast Track designation, and the recently launched Miqnaf (Nafithromycin).
• Zaynich's USFDA review is expected to conclude by mid-2026, targeting life-threatening multi-drug resistant "superbugs."
• Wockhardt is exploring global commercialization strategies, including establishing its own footprint in markets like the US and seeking partnerships, while advocating for regulatory reforms in India.

Why It Matters: Wockhardt aims to be a global leader in novel antibiotics, launching new drugs every 2-3 years.